Uveal Melanoma Clinical Trials (2026): 37 Recruiting Interventional Studies

Last updated: March 9, 2026

Current Clinical Trial Landscape

About uveal melanoma:

Uveal melanoma is the most common primary eye cancer in adults. ~50% develop metastases, most commonly to the liver. Most tumors harbor GNAQ or GNA11 mutations.

Active research areas in 2026:

Tebentafusp and bispecific T-cell engagers (9 trials)
Checkpoint inhibitor combinations (10 trials)
TIL (tumor-infiltrating lymphocyte) therapy
Liver-directed therapies (PHP, hepatic perfusion)

Standard of care: Metastatic: tebentafusp (Kimmtrak) for HLA-A*02:01+ patients. Limited options for HLA-A*02:01- patients. Checkpoint inhibitors have modest activity.

Recruiting Trials by Treatment Setting

Localized / Primary Tumor (Neoadjuvant)

Before or alongside primary treatment (radiation/surgery) for localized disease:

NCT06414590 - Neoadjuvant tebentafusp before primary treatment
NCT07015190 - Neoadjuvant darovasertib (PKC inhibitor) in primary uveal melanoma
NCT05907954 - (Neo)adjuvant IDE196 (darovasertib) in localized ocular melanoma

First-Line Metastatic

For previously untreated metastatic uveal melanoma:

NCT06519266 - PHP + ipilimumab/nivolumab vs ipilimumab/nivolumab alone
NCT06625516 - Tebentafusp + liver-directed therapy
NCT06121180 - Cemiplimab + ziv-aflibercept

Second-Line / Refractory

After progression on first-line therapy:

NCT03686124 - IMA203 TCR-T cell therapy ± nivolumab
NCT03467516 - TIL (tumor-infiltrating lymphocytes) therapy
NCT05607095 - LN-144/LN-145 TIL therapy
NCT07136181 - NBM-BMX novel agent

Adjuvant (High-Risk After Primary Treatment)

NCT06932757 - Adjuvant quisinostat (HDAC inhibitor) in high-risk uveal melanoma

Trials by Treatment Approach

Tebentafusp / Bispecific T-Cell Engagers (9 trials)

Tebentafusp (Kimmtrak) is a bispecific gp100-CD3 T-cell engager approved for HLA-A*02:01+ metastatic uveal melanoma. Trials explore combinations and next-generation agents. View all →

Checkpoint Inhibitors (10 trials)

PD-1/CTLA-4 inhibitors have limited single-agent activity in uveal melanoma; trials test combinations. View all →

TIL / Cellular Therapy

Tumor-infiltrating lymphocyte (TIL) therapy and TCR-T cells show promise in uveal melanoma.

NCT03467516 - TIL adoptive transfer
NCT04119024 - Gene-modified immune cells

Targeted Therapy (GNAQ/GNA11, PKC)

Most uveal melanomas harbor GNAQ or GNA11 mutations, leading to PKC pathway activation.

NCT03947385 - IDE196 (PKC inhibitor) for GNAQ/GNA11-mutant tumors

Liver-Directed Therapies

Percutaneous hepatic perfusion (PHP) and other liver-directed approaches for liver-predominant metastases.

NCT06519266 - PHP + checkpoint inhibitors
NCT07276386 - Melphalan/PHP + tebentafusp

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Find Uveal Melanoma Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition and HLA status.

Find Matching Trials